A proprietary Src homology 2 (SH2) platform of integrated technologies was applied for the discovery of REX-7117 and REX-5376, two highly potent, selective and orally available SH2 domain-targeting STAT3 inhibitors.
Psoriasis is an inflammatory skin disease in which lipid metabolism is often dysregulated. ATP-citrate synthase (ACLY) is known to play a key role in lipid metabolism, but its involvement in psoriasis is not well understood.
Kinesin-like protein KIFC1 plays a role in the clustering of centrosomes in cancer cells and is being investigated in some types of cancer, concretely in melanoma.
Apogee Therapeutics Inc. has selected a development candidate for its APG-990 program, a subcutaneous half-life extended monoclonal antibody targeting OX40L, initially being developed for atopic dermatitis.
Vyne Therapeutics Inc. has received IND clearance from the FDA allowing it to initiate a first-in-human phase Ia study of VYN-202, an oral small-molecule BD2-selective BET inhibitor for autoimmune diseases.
Scientists from the Centre for Genomic Regulation and collaborators have developed a new approach to limiting the amount of collagen produced by hyperactive fibroblasts, which could lead to effective treatments for fibrotic diseases and scarring.
RSS
